

February 8, 1971

Dr. Fred Kagan  
Upjohn Company  
Kalamazoo, Michigan

Dear Fred,

At the APPA meetings this weekend I had the opportunity to speak to Ronald Fieve about rubidium. He has an IND but the restrictions for human trial are severe. To date he has increased dosages gradually to a dose (he could not recall) which seemed insufficient to alter mood or behavior. He does have extensive laboratory data, primarily blood, urine and EEG measurements. These have been summarized in a report to the *Archives of General Psychiatry*, but the report has not yet been accepted for publication.

In addition, he has animal toxicology (3 generations of mice) studies in progress.

He knows of Plotman's public statement but discounts the evidence as inadequate. One basis for his interest is a review of 19th century literature in which he noted many claims of therapeutic benefit.

I was impressed with his enthusiasm and interest. He has a good reputation, and while the evidence for psychoactivity is slim, I would like to hear him discuss his work in public. If your interest is sustained, I am sure he would be pleased to discuss his data.

It is an interesting problem.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kt